2.60
0.78%
+0.02
Adaptive Biotechnologies Corp stock is currently priced at $2.60, with a 24-hour trading volume of 1.97M.
It has seen a +0.78% increased in the last 24 hours and a -19.75% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.59 pivot point. If it approaches the $2.72 resistance level, significant changes may occur.
Previous Close:
$2.58
Open:
$2.54
24h Volume:
1.97M
Market Cap:
$377.24M
Revenue:
$170.28M
Net Income/Loss:
$-225.25M
P/E Ratio:
-1.9549
EPS:
-1.33
Net Cash Flow:
$-167.02M
1W Performance:
+6.56%
1M Performance:
-19.75%
6M Performance:
-44.56%
1Y Performance:
-68.48%
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1551 Eastlake Avenue East, Suite 200, Seattle, WA
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-05-23 | Resumed | JP Morgan | Overweight |
Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-25-22 | Initiated | Credit Suisse | Underperform |
Jun-03-22 | Initiated | Piper Sandler | Neutral |
Feb-16-22 | Reiterated | BTIG Research | Buy |
Feb-16-22 | Reiterated | BofA Securities | Buy |
Feb-16-22 | Reiterated | Goldman | Neutral |
Feb-16-22 | Reiterated | JP Morgan | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
Oct-08-20 | Resumed | BTIG Research | Buy |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Jun-03-20 | Initiated | Goldman | Buy |
Jul-23-19 | Initiated | BTIG Research | Buy |
Jul-22-19 | Initiated | BofA/Merrill | Buy |
Jul-22-19 | Initiated | Cowen | Outperform |
Jul-22-19 | Initiated | Goldman | Neutral |
Jul-22-19 | Initiated | Guggenheim | Buy |
Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
Benzinga
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
GlobeNewswire Inc.
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
GlobeNewswire Inc.
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS
Zacks Investment Research
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Adaptive Biotechnologies Corp (ADPT) Revenue 2024
ADPT reported a revenue (TTM) of $170.28 million for the quarter ending December 31, 2023, a -8.11% decline year-over-year.
Adaptive Biotechnologies Corp (ADPT) Net Income 2024
ADPT net income (TTM) was -$225.25 million for the quarter ending December 31, 2023, a -12.48% decrease year-over-year.
Adaptive Biotechnologies Corp (ADPT) Cash Flow 2024
ADPT recorded a free cash flow (TTM) of -$167.02 million for the quarter ending December 31, 2023, a +16.61% increase year-over-year.
Adaptive Biotechnologies Corp (ADPT) Earnings per Share 2024
ADPT earnings per share (TTM) was -$1.56 for the quarter ending December 31, 2023, a -10.64% decline year-over-year.
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Cap:
|
Volume (24h):